Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice

Blood

Volumn 95, Issue 2, 2000, Pages 577-580

  Eitzman, Daniel T ^a,b,c   Westrick, Randal J ^a,b   Nabel, Elizabeth G ^a,b   Ginsburg, David ^a,b  

^a Department of Internal Medicine   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR; VITRONECTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL INJURY; BLOOD VESSEL OCCLUSION; CONTROLLED STUDY; FIBRINOLYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; RISK ASSESSMENT; THROMBOSIS;

EID: 0034650976     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.2.577     Document Type: Article

References (28)

1. Fuster V, Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardia! infarction: insights from studies of vascular biology. Circulation. 1994;90:2126-2146.
2. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood. 1991;78: 3114-3124.
3. Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb 1989:9:87-115.
4. Declerck PJ, De Mol M, Alessi MC, et al. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin).JBiolChem. 1988:263:15,454-15,461.
5. Zheng X, Saunders TL, Camper SA, Samuelson LC, Ginsburg D. Vïtronectin is not essential for normal mammalian development and fertility. Proc Natl Acad Sei U S A. 1995;92:12,42612,430.
6. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature. 1996;383: 441-443.
7. Schleef RR, Higgins DL, Pillemer E, Levitt U. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest. 1989:83:1747-1752.
8. Dieval J, Nguyen G, Gross S, Delobel J, Kruithof EKO. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor. Blood. 1991:77:528-532.
9. Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D. Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frameshift mutation. N Engl J Med. 1992:327:17291733.
10. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985:313: 1557-1563.
11. Wiman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin Thromb Hemost. 1990;16: 207-216.
12. Carmeliet P, Collen D. Genetic analysis of the plasminogen and coagulation system in mice. Haemostasis Suppl. 1996:4:132-153.
13. Carmeliet P, Stassen JM. Schoonjans L, et al. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest. 1993;92:2756-2760.
14. Eitzman DT, McCoy RD, Zheng X, et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest. 1996:97:232-237.
15. Fartehi PM, Ozaki CK, Carmeliet P, Fay WP. Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice. Circulation. 1998:97:1002-1008.
16. Carmeliet P, Kieckens L, Schoonjans L, et al. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest. 1993:92: 2746-2755.
17. Brown SL, Uundgren CH, Nordt T, Fujii S. Stimulation of migration of human aortic smooth muscle cells by vitronectin: implications for atherosclerosis. Cardiovasc Res. 1994:28:18151820.
18. Biemond BJ, Levi M, Coronel R, Janse MJ, ten Gate JW, Pannekoek H. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1 -neutralizing monoclonal antibody. Circulation. 1995:91:1175-1181.
19. Fay WP, Eitzman DT, Shapiro AD, Madison EL, Ginsburg D. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1 -dependent and-independent mechanisms. Blood. 1994;83: 351-356.
20. Eitzman DT, Fay WP, Lawrence DA, et al. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J Clin Invest. 1995:95:2416-2420.
21. Matsuno H, Uematsu T, Nagashima S, Na-kashima M. Photochemically induced thrombosis model in rat femoral artery and evaluation of effects of heparin and tissue-type plasminogen activator with use of this model. J Pharmacol Methods. 1991;25:303-317.
22. Imura Y, Kiyota Y, Nagai Y, Nishikawa K, Terashita 2. Beneficial effect of CV-4151 (Isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model. Thromb Res. 1995:79:95-107.
23. Takiguchi Y, Hirata Y, Wada K, Nakashima M. Arterial thrombosis model with photochemical reaction in guinea-pig and its property. Thromb Res. 1992:67:435-445.
24. Kikuchi S. Umemura K, Kondo K, Saniabadi AR, Nakashima M. Photochemically induced endothelial injury in the mouse as a screening model for inhibitors of vascular intimai thickening. Arterioscler Thromb Vase Biol. 1998; 18:1069-1078.
25. Kawasaki T, Kaida T, Amout J, Vermylen J. A new animal model of thrombophilia confirms that high plasma factor VIII levels are thrombogenic. Thromb Haemost. 1999:81:306-311.
26. Carmeliet P, Moons L, Stassen J-M, et al. Vascular wound healing and neointima formation induced by perivascular electric injury in mice. Am J Pathol. 1997:150:761-776.
27. Matsuno H, Kozawa O, Niwa M, et al. Differential role of components of the fibrinolytic system in the formation and removal of thrombus induced by endothelial injury. Thromb Haemost. 1999:81 : 601-604.
28. Fay W, Parker A, Ansari M, Zheng X, Ginsburg D. Vitronectin inhibits the thrombotic response to arterial Injury in mice. Blood. 1999:93:1825-1830.